122 studies found for:    "Expanded Access" [STUDY-TYPES] | Open Studies
Show Display Options
Rank Status Study
21 Available Dextromethorphan Added on for the Patients With ADHD
Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: Dextromethorphan
22 Available Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination
Conditions: Toxicity Due to Chemotherapy;   Impaired 5FU Elimination
Intervention: Drug: uridine triacetate
23 Available PFO ACCESS Registry
Conditions: Patent Foramen Ovale;   Stroke
Intervention: Device: Device closure with the AMPLATZER PFO Occluder
24 Available An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
Condition: Metastatic Breast Cancer
Intervention: Drug: Eribulin Mesylate
25 Available Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Condition: Hypertension, Pulmonary
Intervention: Drug: Adempas (Riociguat, BAY63-2521)
26 Unknown  Using Hypnotherapy For Dementia & Alzheimer's
Condition: Alzheimer Disease
Intervention: Other: Hypnotherapy
27 Available Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
Condition: Unresected Stage IIIb to IVM1c Melanoma
Intervention: Drug: Talimogene Laherparepvec
28 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
29 Available A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma
Condition: Liver Cancer
Intervention: Device: Theraspheres
30 Available Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: nintedanib
31 Available Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome
Condition: Dravet Syndrome
Intervention: Drug: Stiripentol
32 Available An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Condition: Differentiated Thyroid Cancer
Intervention: Drug: Lenvatinib
33 Available Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease
Condition: Byler Disease
Intervention: Drug: RAVICTI
34 Available Effect of Genes on Rosuvastatin Therapy for Hyperlipidemia
Condition: Hyperlipidemia
Interventions: Drug: rosuvastatin,fenofibrate;   Genetic: CYP2C9, UGT1A1, UGT1A3, OATP2, BCRP
35 Available Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
Condition: Lambert Eaton Myasthenic Syndrome
Intervention: Drug: 3, 4-Diaminopyridine
36 Available Accuracy and Reliability of GSA for Remnant Liver Function
Condition: Both Benign and Malignant Liver Mass
Intervention: Device: 99mTc-GSA
37 Available Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
38 Available Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
Conditions: Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE);   Juvenile Dermatomyositis (JDM);   Stimulator of Interferon Genes (STING)-Associated Vasculitis With Onset in Infancy (SAVI)
Intervention: Drug: Baricitinib
39 Unknown  Expanded Access Protocol Using I131-MIBG
Conditions: Neuroblastoma;   Pheochromocytoma;   Paraganglioma
Intervention: Radiation: I-131 MIBG
40 Available Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)
Condition: Melanoma
Intervention: Biological: Pembrolizumab

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years